{"id":"W3171042793","doi":"10.1016/j.ctarc.2021.100405","title":"Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Cilag; Takeda Oncology; Chugai Pharmaceutical; Genentech; Aptitude Health; Sierra Oncology; Sociedad Española de Oncología Médica; PharmaMar; European Society for Medical Oncology; Oryzon Genomics; Astellas Pharma; Eisai; MacroGenics; Mersana Therapeutics; Agios Pharmaceuticals; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Pfizer; Incyte; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Array BioPharma; Daiichi Sankyo Europe; Servier; Gilead Sciences; Glenmark Pharmaceuticals; AbbVie; Exelixis; Sanofi; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; EUSA Pharma; AstraZeneca; Argenx; American Society of Clinical Oncology; GlaxoSmithKline; Amgen; LAM Therapeutics; Celgene","keywords":"Tolerability; Medicine; Internal medicine; Adverse effect; Lung cancer; Oncology; Pharmacokinetics; Pleural effusion; Clinical trial; Gastroenterology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001856497,0.0001630353,0.0003567203,0.0001891055,0.0002529662,0.00002597848,0.000167271,0.00003651434,0.0000535356],"category_scores_gemma":[0.00004482567,0.0001063402,0.00002536048,0.0006168048,0.0007104309,0.00005662415,0.0003743176,0.0003149877,4.850131e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006712244,"about_ca_system_score_gemma":0.0009659528,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002405861,"about_ca_topic_score_gemma":0.003397267,"domain_scores_codex":[0.9985398,0.0001926417,0.0002097307,0.000312846,0.0003785153,0.0003664435],"domain_scores_gemma":[0.9977266,0.0004020361,0.00005526322,0.0007897028,0.0008565847,0.0001698374],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001556904,0.001653207,0.9725138,0.000390369,0.0006083159,0.00001496886,0.001612649,0.00002489934,0.0004828519,0.0000599922,0.0002096188,0.02087243],"study_design_scores_gemma":[0.02819688,0.001658206,0.9535766,0.001096566,0.0003995987,0.000003542631,0.0005269516,0.0002600795,0.005527779,0.00001075973,0.008552388,0.0001906688],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.924476,0.06449292,0.000004274679,0.00735527,0.00001194514,0.001353031,0.0001094543,0.00001462461,0.002182429],"genre_scores_gemma":[0.8775381,0.1198603,0.0008551662,0.00002758349,0.00002270557,0.0004832391,0.00007706212,0.00002429898,0.001111553],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05536741,"threshold_uncertainty_score":0.4336429,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06452351404831635,"score_gpt":0.4140582255718726,"score_spread":0.3495347115235562,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}